Literature DB >> 2367283

A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat.

R N Hunsinger1, D Wright.   

Abstract

Fenfluramine (FN) is a potent serotonin-releasing drug used primarily as an anorectic agent. The symptomatology of its acute lethality has been well documented in animal models such as the rat. A very prominent feature of this lethality profile is hypoxia, as demonstrated by the onset of severe cyanosis just prior to death. It is not clear in the literature whether this hypoxia is the result of a direct pulmonary effect or is secondary to cardiac injury. To further characterize this aspect of FN's toxicity, respiratory and electrocardiographic measurements were taken in anaesthetized rats subjected to high doses of FN (129.6 mg/kg, i.p.). Death occurred in these animals within 15 min of drug administration, apparently as the result of abrupt respiratory cessation, followed by cardiac ischaemia. No significant gross or histopathological lesions were evident in these animals. In other trials, prior treatment with diethylcarbamazine (DEC) was found to potentiate the lethality of FN, while cyproheptadine (CHP) pretreatment attenuated FN's toxic effects. Necropsies, conducted 24 h after FN administration, revealed widespread alveolar and pulmonary interstitial haemorrhage in the CHP-pretreated animals. The data suggest that high doses of FN directly result in pulmonary hypertension, which secondarily induces ischaemic cardiac injury.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2367283     DOI: 10.1016/1043-6618(90)90735-v

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Cardiotoxic effects of fenfluramine hydrochloride on isolated cardiac preparations and ventricular myocytes of guinea-pigs.

Authors:  S Rajamani; C Studenik; R Lemmens-Gruber; P Heistracher
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Appetite suppressants and primary pulmonary hypertension in the United Kingdom.

Authors:  S H Thomas; A Y Butt; P A Corris; J J Egan; T W Higenbottam; B P Madden; P C Waller
Journal:  Br Heart J       Date:  1995-12

3.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.